Skip to content

Rumble, Inc. RUM Deferred Issuance Costs Included In Accounts Payable And Accrued Liabilities

Deferred Issuance Costs Included In Accounts Payable And Accrued Liabilities at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$0-100%
Precigen logo
PrecigenPGEN
$0-100%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$7.5K
CG Oncology logo
CG OncologyCGON
$139K-35.3%
NetSTREIT logo
NetSTREITNTST
$502K+1,992%
Beta Technologies
 logo
Beta Technologies BETA
$195K-97.9%

Other financials

Income statement

See full
Revenue$25.5M+7.4%
Gross profit-$1.5M+75.7%
Operating income-$39.1M-7.5%
Net income-$30.3M-1,042%
EPS (diluted)-$0.12-1,100%

Balance sheet

See full
Cash & equivalents$219.0M+2,198%
Total debt$1.6M+1.1%
Total equity$249.9M-26.4%
Total assets$311.2M-20.4%

Cash flow

See full
Operating cash flow-$16.6M-14.6%
CapEx$1.1M+731%
Free cash flow-$17.7M-21.1%

Valuation

See full
Market cap$1.71B-27.7%

Profitability

See full
Gross margin-12.1%-5.4pp
Operating margin-126.4%-3.7pp
Net margin-106.9%-41.5pp
FCF margin-75.8%+8.2pp

Returns & leverage

See full
Return on equity-37.1%-14.7pp
Debt / equity0.0×
Current ratio4.7×-5.2×

Where this comes from

Reported directly by Rumble, Inc. in its filing.

Tagged under the XBRL concept rum:DeferredIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities.

The official record: Rumble, Inc.’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rumble, Inc.'s deferred issuance costs included in accounts payable and accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rumble, Inc.'s deferred issuance costs included in accounts payable and accrued liabilities?
Rumble, Inc. (RUM) reported deferred issuance costs included in accounts payable and accrued liabilities of $220K in Q4 2024.
What does deferred issuance costs included in accounts payable and accrued liabilities mean?
This metric tracks costs related to the issuance of securities that have been accrued but not yet paid in cash. It serves as a bridge between accounting accruals and future cash outflows for financing activities.